Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)

Uppsala University41 enrolled

Overview

The purpose of this study is to investigate the metabolic consequences of a moderate weight gain and if the type of dietary fat (saturated versus polyunsaturated) can modify the effects in young healthy adults. Hypothesis: the type of dietary fat can modify the effects of weight gain.

Specific goals: * Investigate if dietary fat composition influences liver fat accumulation and metabolic risk factors in response to moderate weight gain * Investigate if polyunsaturated fat (PUFA) in the diet could counteract any unfavorable metabolic changes that are expected to accompany moderate weight gain * Investigate effects of weight gain and dietary fat composition on markers of vascular health

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

Polyunsaturated fatty acid groupOTHER

Addition of polyunsaturated fatty acids to the diet in the form of pastries

Saturated fatty acid groupOTHER

Addition of saturated fatty acids to the diet in the form of pastries

Eligibility

Sex: ALLMin age: 20 YearsMax age: 38 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy, * Body Mass Index 18-27 Exclusion Criteria: * Liver disease, * Coronary heart disease, * Diabetes mellitus, * Malignant diseases, * Alcohol or drug abuse, * Magnetic Resonance-incompatibility, * Abnormal clinical chemistry, * Use of drugs that significantly effects energy metabolism, * Heavy exercise, * Pregnancy or lactation, * Allergy of gluten, egg or milk protein

Locations (1)

Uppsala University Hospital, Uppsala Science Park

Uppsala, Sweden

Outcomes

Primary Outcomes

Hepatic steatosis by magnetic resonance tomography (MRT)

Time frame: 6 weeks

Secondary Outcomes

high density lipoprotein (HDL)

Time frame: 6 weeks

low density lipoprotein (LDL)

Time frame: 6 weeks

Insulin

Time frame: 6 weeks

Glucose

Time frame: 6 weeks

Triglycerides

Time frame: 6 weeks

Cholesterol

Time frame: 6 weeks

Apolipoprotein B (ApoB)

Time frame: 6 weeks

Apolipoprotein A1 (ApoA1)

Time frame: 6 weeks

Aspartate aminotransferase (ASAT)

Time frame: 6 weeks

Alanine aminotransferase (ALAT)

Time frame: 6 weeks

Gamma glutamyl transpeptidase (GGT)

Time frame: 6 weeks

Homeostasis model of assessment insulin resistance (HOMA-IR)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.